Deutsche Bank Aktiengesellschaft Upgrades Gilead Sciences (NASDAQ:GILD) to “Buy”

Gilead Sciences (NASDAQ:GILD) was upgraded by investment analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note issued on Tuesday,Briefing.com Automated Import reports. The firm currently has a $120.00 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 15.30% from the stock’s current price.

Several other equities analysts have also weighed in on the company. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their target price for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Finally, Oppenheimer boosted their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Stock Down 1.8 %

Shares of NASDAQ:GILD opened at $104.08 on Tuesday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock has a market cap of $129.71 billion, a price-to-earnings ratio of 1,156.44, a P/E/G ratio of 1.25 and a beta of 0.18. The company has a 50 day moving average of $94.14 and a 200-day moving average of $87.89. Gilead Sciences has a one year low of $62.07 and a one year high of $106.69.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. On average, sell-side analysts forecast that Gilead Sciences will post 4.35 earnings per share for the current year.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 137,676 shares of Gilead Sciences stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total value of $14,073,240.72. Following the completion of the transaction, the chief financial officer now owns 171,223 shares of the company’s stock, valued at $17,502,415.06. This trade represents a 44.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 710,500 shares of company stock worth $67,684,956 over the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GILD. Norges Bank acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $1,789,254,000. FMR LLC lifted its holdings in Gilead Sciences by 79.4% during the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after purchasing an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP boosted its stake in Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares during the period. Pacer Advisors Inc. grew its holdings in Gilead Sciences by 723.3% in the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock valued at $594,370,000 after buying an additional 5,653,075 shares in the last quarter. Finally, Northern Trust Corp increased its position in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock worth $1,377,707,000 after buying an additional 2,458,954 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.